Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PYGB | P11216 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573708 | 1.00 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL22431361 | 1.00 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL20842452 | 1.00 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL17771655 | 0.91 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL12936319 | 0.91 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL23735602 | 0.87 | MAPK1 (0.56) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL14473245 | 0.87 | ALDH1A1 (0.46) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL16393013 | 0.87 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1SMN1; SMN2PYGB | |
| SCHEMBL23640116 | 0.85 | CD69 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 | |
| SCHEMBL23640154 | 0.85 | CD69 (0.58) | ALDH1A1THRBMAPK1SMN1; SMN2CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-07-11 | — | — | US | disclosed |
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-05-02 | — | — | US | disclosed |
| US-9982257-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9885037-B2 | — | — | 2018-02-06 | — | — | US | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | ALDH1A1 3613/4885THRB 3541/4885MAPK1 4822/4885 |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | ALDH1A1 4085/4885THRB 3143/4885MAPK1 4368/4885 |
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | RXFP1, AVPR2, RXFP3 | ALDH1A1 2641/4885THRB 3616/4885MAPK1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.